|
polyps
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Both LAMN and HAMN harbored mutations of KRAS (9/9 and 8/8 [100%], respectively) and GNAS (5/8 [63%] and 5/9 [56%], respectively) in significantly higher proportions than MACA (KRAS, 7/10 [70%, P=0.04]; GNAS: 1/10 [10%, P=0.02]) and serrated polyps (KRAS, 1/5 [20%, P=.0007]; GNAS: 0/5 [0%, P=0.04]).
|
31491041 |
2020 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS alterations were present in 30% of polyps.
|
31152544 |
2019 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Laser microdissection-based sequencing analysis showed that BRAF or KRAS mutations were shared between TSA and precursor polyps in all lesions.
|
30179900 |
2019 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF-mutated polyps were more likely than KRAS-mutated polyps to arise in a precursor polyp (82% versus 18%, P < 0.001), and were more likely to have slit-like serrations (100% versus 73%, P = 0.003).
|
30007084 |
2018 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Patients were classified into 3 subgroups, based on the polyp mutational profile at baseline, as follows: non-mutated polyps (Wild-type), at least one BRAF-mutated polyp, or at least one KRAS-mutated polyp.
|
28953955 |
2017 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS mutations were observed in all types of polyps, but were most commonly encountered in tubulovillous adenomas and TSAs.
|
26924569 |
2016 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In conclusion, our results indicate that MLH1-hypermethylated BRAF wild-type colorectal carcinomas can harbor KRAS mutations and arise from precursor polyps resembling conventional tubular/tubulovillous adenomas.
|
27438990 |
2016 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF mutant traditional serrated adenomas were more frequently proximal (39% versus 2%; P≤0.0001), were exclusively associated with a precursor polyp (57% versus 0%; P≤0.0001), and were more frequently CpG island methylator phenotype high (60% versus 16%; P≤0.0001) than KRAS mutant traditional serrated adenomas.
|
25216220 |
2015 |
|
polyps
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hyperplastic polyps of the colon and rectum - reclassification, BRAF and KRAS status in index polyps and subsequent colorectal carcinoma.
|
25708741 |
2015 |
|
polyps
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
KRAS mutant colonic polyps and cancer tissue had significantly higher (3.04 fold, 95% CI=1.23-7.46) expression levels of hsa-miR-135b compared to polyps and cancers with non mutant KRAS gene (p=0.001).
|
25496852 |
2015 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
There was a strong association between germinal MUTYH mutation and KRAS Gly12Cys somatic mutation in polyps.
|
24470512 |
2014 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The analysis of MUTYH-associated polyposis cases of the EPIPOLIP cohort confirms the importance of including serrated polyps in the diagnostic work-up of patients with oligopolyposis, suggests a role for screening polyps for the somatic c.34G>T KRAS mutation, and allows the implementation of a genetic testing strategy based on population data.
|
24486588 |
2014 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Importantly, BRAF-mutated TSAs had more widespread methylation of a 5-marker CpG island panel compared with KRAS-mutated polyps.
|
25127095 |
2014 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
A per-patient analysis revealed that all patients had a BRAF or KRAS mutation in more than 25% of their polyps; 84.8% of patients had a mutation in BRAF or KRAS in more than 50% of their polyps.
|
23376323 |
2013 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Compared with tumors demonstrating neither BRAF nor KRAS mutation, KRAS-mutated carcinomas showed more frequent location in the proximal colon (41 vs 27%; P=0.001), mucinous differentiation (46 vs 25%; P<0.001), presence of a contiguous polyp (38 vs 22%; P<0.001), MGMT methylation (47 vs 26%; P=0.01) and loss of MGMT immunohistochemical expression (27 vs 19%; P=0.02).
|
23348904 |
2013 |
|
polyps
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Mutations in BRAF and KRAS and mismatch repair protein expression were determined in a subset of polyps.
|
22510757 |
2012 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Allelic imbalance, MGMT methylation, and K-RAS mutations arise in 62%, 39%, and 32% of polyps, respectively.Only 14% of polyps had no alterations.
|
21238786 |
2011 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
With regard to HP, KRAS mutations were present in 31.1% of polyps and BRAF mutations in 46.7% of polyps.
|
21836485 |
2011 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF mutations were common (11 out of 21 polyps), whilst KRAS mutations were identified in 4 of 21 polyps.
|
21347319 |
2011 |
|
polyps
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We report a series of 9 serrated polyps arising in the duodenum with clinicopathologic features, immunohistochemical expression profile of mucins (MUC2, MUC5AC, MUC6), and molecular analysis for BRAF and KRAS.
|
21733555 |
2011 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF and KRAS mutation analysis were employed to further validate polyp discrimination.
|
19172291 |
2009 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS, PIK3CA or BRAF occur in 71% of polyps and were mutually exclusive.KRAS mutations occur in 35% of polyps.PIK3CA was found in one of the polyps.
|
18782444 |
2008 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We examined the presence of HPs and sessile serrated adenomas (SSAs) in 17 MAP patients and studied the occurrence of G:C-->T:A transversions in the APC and K-ras gene in these polyps.
|
19013464 |
2008 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
KRAS and BRAF mutation analysis was also performed on a subset of polyps from 2 patients.
|
18223333 |
2008 |
|
polyps
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Fifty nondysplastic serrated polyps (6 SSPs, 31 study polyps, and 13 MVHPs) were evaluated for Ki-67, O6-methylguanine methyltransferase, MUC2, and MUC5AC expression, and also their BRAF and KRAS mutational status.
|
18300810 |
2008 |